ArticleMolecular biology reports2026
Ex vivo expanded autologous hematopoietic stem cells stimulate improved immunogenic activity: an in-vitro preliminary study for future clinical uses.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematopoietic stem cell therapy is a cornerstone of regenerative medicine for treating haematological and immunological disorders. While autologous HSCs avoid the complications of graft-versus-host disease, current expansion protocols often rely on expensive synthetic media and xeno-derived components that hinder clinical translation. This study evaluates a minimalist, "in-house" expansion protocol designed for cost-effectiveness and complete human and Malaysian cGMP process compatibility.
methodsCD34 + cells were isolated from the peripheral blood of healthy donors and expanded using the in-house methodology consisting of autologous plasma supplemented with stem cell factor and interleukin-3. The expanded HSCs were co-cultured with autologous peripheral blood mononuclear cells to assess their stimulatory potential. Parameters measured included cell viability, cell purity, total white blood cell expansion event counts via flow cytometry, and Interferon-gamma secretion via ELISA.
resultsThe expansion protocol achieved good results, with viable CD34 + purity and a marginal CD71 + percentage. Functional assays revealed that the presence of expanded HSCs exerted a potent stimulatory effect on the immune environment. The co-culture group containing expanded HSCs and corresponding donor PBMC demonstrated a strong increase in total WBC event counts, reaching around average 3000 counts compared to counts < 500 and even less in the control group. Furthermore, this interaction induced strong immunogenic activity, characterised by high levels of IFN-gamma secretion, whereas the control groups showed negligible cytokine production.
conclusionsThese findings demonstrate that ex vivo expanded autologous HSCs act as a strong biological stimulant, significantly aiding leukocyte proliferation and immune signalling. Our expansion methodology provides a safe, human-compatible, and effective framework for good improvement of such haematological factors. These results further corroborate the potential for this approach in future clinical therapies aimed at boosting immune recovery, overall patient wellness and haematological parameters.
Indexed as
Identifiers
42461489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.